A Multicentre Prospective Randomized Open-Label 12-Week Study With Blinded Evaluation Comparing the Efficacy and Safety of Irbesartan and Irbesartan-Hydrochlorothiazide Fixed Combination With Amlodipine and Amlodipine Plus Hydrochlorothiazide in Elderly Patients With Isolated Systolic Hypertension.

Trial Profile

A Multicentre Prospective Randomized Open-Label 12-Week Study With Blinded Evaluation Comparing the Efficacy and Safety of Irbesartan and Irbesartan-Hydrochlorothiazide Fixed Combination With Amlodipine and Amlodipine Plus Hydrochlorothiazide in Elderly Patients With Isolated Systolic Hypertension.

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Jul 2009

At a glance

  • Drugs Irbesartan/hydrochlorothiazide (Primary) ; Amlodipine; Hydrochlorothiazide; Irbesartan
  • Indications Isolated systolic hypertension
  • Focus Therapeutic Use
  • Acronyms AMISH
  • Sponsors Sanofi
  • Most Recent Events

    • 14 May 2008 Results have been presented at the 23rd Annual Scientific Meeting of the American Society of Hypertension.
    • 13 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top